Genflow Strengthens IP Portfolio

Core Viewpoint - Genflow Biosciences Plc has filed a patent examination request in China for its SIRT6 Variants aimed at treating Non-Alcoholic Steatohepatitis (NASH), highlighting its commitment to expanding its intellectual property portfolio in the longevity sector [1]. Group 1: Company Developments - Genflow is the only publicly listed longevity company in Europe, indicating its unique position in the market [1]. - The patent application focuses on proprietary variants of the SIRT6 gene, which are designed to address NASH, a severe liver disease with limited treatment options [1]. Group 2: Industry Context - Non-Alcoholic Steatohepatitis (NASH) is identified as a progressive liver disease, emphasizing the need for innovative treatment solutions in this area [1].